QT Imaging Holdings Stock Price, News & Analysis

QT Imaging (OTCQB: QTIH) appointed Satrajit Misra as Chief Commercial Officer effective November 10, 2025. The newly created CCO role will lead commercial scale-up and clinical partnerships as the company pivots toward a SaaS and biomarker-driven franchise and seeks wider adoption of its radiation-free, contrast-free, compression-free breast imaging technology.

Misra brings ~30 years of radiology, oncology and molecular imaging experience, most recently as Executive SVP, Chief Sales and Marketing Officer at Canon Medical Systems USA, and prior roles at Philips and Siemens. He will focus on accelerating product pipeline development, market expansion, and shareholder value.

QT Imaging (OTCQB: QTIH) will release its third quarter 2025 financial results after market close on Tuesday, November 11, 2025. Management will host a webcasted conference call the same day to review results and provide a business update.

Conference call details: 4:30 p.m. ET; domestic dial-in 1-877-545-0523; international dial-in 973-528-0016; access code 457613. The call will be broadcast live and archived on the company website.

QT Imaging (OTCQB: QTIH) will present at RSNA 2025 in Chicago, Nov 30–Dec 4, 2025. Chief Medical Officer Elaine luanow, MD will deliver a seminar titled “Quantitative Transmission Imaging Technology: The Future of Breast Imaging with Safe Volumetric Ultrasound” on Dec 3 at 1:00 PM CT at the Canon Workshop (Booth #8349, North Hall).

Attendees are invited to live demonstrations of the company’s FDA-cleared QTI Breast Acoustic CT scanner at Booth #6713, a non‑invasive 3D breast imaging system that requires no compression, contrast, or ionizing radiation.

QT Imaging (OTCQB: QTIH) announced a strategic collaboration with Intelerad Medical Systems on October 28, 2025 to deploy InteleShare Research PACS and Cloud PACS across QT Imaging’s clinical research and commercial networks.

The partnership enables browser-based viewing, image anonymization, secure cloud archiving, EHR integration, and multi-institutional data sharing for QT Imaging’s Breast Acoustic CT scanners. QT Imaging plans to deliver its Cloud SaaS platform and future AI/ML modules (automated lesion segmentation, volumetric tissue characterization, diagnostic support) via InteleShare’s DICOM-compatible cloud architecture to connected systems.

QT Imaging (OTCQB: QTIH) implemented a 3:1 reverse stock split of its common stock that became market effective on October 24, 2025. The company disclosed that FINRA referenced the market effectiveness in its Form 8-K dated October 23, 2025.

Public warrants were adjusted so each warrant is exercisable for 0.33333809 shares and the warrant exercise price was increased on a 2.9999572:1 basis from $2.30 to $6.90. Continental Stock Transfer and Trust Company is acting as exchange agent; book-entry holders need take no action, while certificated holders will receive a letter of transmittal with surrender instructions.

QT Imaging (OTCQB: QTIH) announced on October 20, 2025 that it has applied to relist on the Nasdaq Capital Market and approved a 3:1 reverse stock split to meet Nasdaq's $4.00 minimum bid requirement. The board fixed the 3:1 ratio on October 17, 2025 and the split becomes effective at 4:01 p.m. EDT on October 23, 2025, with split-adjusted trading resuming on the OTCQB on October 24, 2025 under the symbol QTIH. Share count will decrease from 35,671,332 to 11,890,444 shares before rounding; after rounding for fractional shares the company expects at least ~11,890,612 shares outstanding. New CUSIP: 746962307. CST is the exchange agent; eligible holders need not take action.

QT Imaging Holdings (OTCQB: QTIH), a medical device company focused on innovative body imaging systems, has secured an $18 million PIPE financing through a private placement. The company is selling approximately 12.12 million shares at $1.50 per share, along with equivalent warrants exercisable at the same price for five years.

The financing, anchored by Sio Capital Management, will be used to repay $5 million of senior secured term loan to Lynrock Lake Master Fund LP, expand U.S. and global market activities, and deploy the QTI Cloud Platform. Additionally, the company is preparing to initiate its NASDAQ relisting process.

QT Imaging Holdings (OTCQB: QTIH), a medical device company focused on innovative body imaging systems, has appointed Jay Jennings as its new Chief Financial Officer, effective September 2, 2025. Jennings, who brings nearly 30 years of executive management experience, will replace current CFO Anastas Budagov.

Jennings' impressive track record includes leading two go-public transactions, managing finance teams of up to 100 employees, and involvement in 12 business acquisitions. He previously served as Acting CEO and CFO at UpHealth, Inc., and held executive roles at eHealth, Inc. and MetaCreation Corporation. The appointment aligns with QT Imaging's strategic goals of evolving into a scalable imaging platform and pursuing a Nasdaq uplisting.

QT Imaging Holdings (OTCQB: QTIH), a medical device company focused on innovative body imaging systems, has secured $5.0 million in additional financing through an amended senior secured term loan from Lynrock Lake Master Fund LP. The company utilized these funds to fully repurchase warrants held by Yorkville (YA II PN, Ltd.), which consisted of 15,000,000 shares at $0.40 per share.

CEO Dr. Raluca Dinu expressed confidence in the company's future outlook, emphasizing that the current stock valuation presents an attractive investment opportunity to enhance long-term shareholder value.